Crescent Biopharma (CBIO) Change in Account Payables (2013 - 2026)
Crescent Biopharma (CBIO) reported Change in Account Payables of -$2.3 million for Q1 2026, down 546.33% year-over-year from $518000.0 in Q1 2025, and down 325.78% quarter-over-quarter from $1.0 million in Q4 2025.
Crescent Biopharma (CBIO) Change in Account Payables (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has 14 years of Change in Account Payables data on file, last reported at -$2.3 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at -$2.3 million, down 546.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$749000.0 (down 131.44% YoY), and the FY2025 annual result was $2.1 million, up 486.22% from the prior year.
- Change in Account Payables slipped to -$2.3 million in Q1 2026 per CBIO's latest filing, from $1.0 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $1.6 million in Q3 2024 and troughed at -$2.3 million in Q1 2026.
- A 5-year average of $16538.1 and a median of $107000.0 in 2024 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2024 and 2025: Change in Account Payables surged 1667.01% in 2024, then slumped 586.1% in 2025.
- A 5-year view of Change in Account Payables shows it stood at $118066.0 in 2022, then jumped by 355.87% to $538230.0 in 2023, then sank by 80.12% to $107000.0 in 2024, then soared by 857.01% to $1.0 million in 2025, then sank by 325.78% to -$2.3 million in 2026.
- Business Quant data shows CBIO's Change in Account Payables at -$2.3 million in Q1 2026, $1.0 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - | -2.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.31 Mn |
| Mar 31, 2026 | -2.31 Mn |
| Dec 31, 2025 | 1.02 Mn |
| Dec 31, 2025 | 1.02 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Jun 30, 2025 | -949,000.00 |
| Jun 30, 2025 | -949,000.00 |
| Mar 31, 2025 | 518,000.00 |
| Mar 31, 2025 | 518,000.00 |
| Dec 31, 2024 | 107,000.00 |
| Dec 31, 2024 | 107,000.00 |
| Sep 30, 2024 | 1.56 Mn |
| Sep 30, 2024 | 1.56 Mn |
| Jun 30, 2024 | 195,229.00 |
| Jun 30, 2024 | 195,229.00 |
| Mar 31, 2024 | -112,581.00 |
| Mar 31, 2024 | -112,581.00 |
| Dec 31, 2023 | 538,230.00 |
| Dec 31, 2023 | 538,230.00 |